NASDAQ$IDXX

IDEXX Laboratories Inc · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Briefing

IDEXX reported a revenue increase of 19% and EPS increase of 93% for Q4 2020.

IDEXX Laboratories announced strong Q4 and full year 2020 results, driven by high growth in Companion Animal Group (CAG) Diagnostics recurring revenue and sustained growth in the Livestock, Poultry and Dairy (LPD) business. Q4 revenue increased by 19% and EPS increased by 93%.

  • Achieved fourth quarter reported revenue growth of 19% and organic growth of 17%.
  • CAG Diagnostics recurring revenue reported growth of 23% and organic growth of 21%.
  • Full year EPS of $6.71, an increase of 37% on a reported basis.
  • Provided initial outlook for 2021 revenue of $3,065 million - $3,120 million, reflecting reported growth of 13% - 15.5%.

Headline financials

Total Revenue

$721M

Previous: $605M+19.1%
EPS (adj)

$1.76

Previous: $1.04+69.2%
Capital Expenditures

$14.2M

Previous: $45.9M-69.1%
Free Cash Flow

$205M

Previous: $110M+87.0%
Net Income

$175M

Previous: $90.5M+93.2%
Operating Income

$185M

Previous: $116M+60.1%
Gross Profit

$410M

Previous: $331M+23.7%
Cash & Equivalents

$384M

Previous: $90.3M+325.0%
Total Assets

$2.29B

Previous: $1.83B+25.2%
Stock-Based Comp

$7.94M

Previous: $16.7M-52.3%

Revenue & EPS history

IDEXX · Revenue · Quarterly

$721M

Q4 2020+19.1%vs Q4 2019
Beat estimate in 16 of 16 quarters(100%)
ActualEstimate

Revenue by segment

IDEXX · $829M total across 9 segments · Q4 2022

  • Reference labs
    $283M+4.2%
  • VetLab consumables
    $261M+3.8%
  • Rapid assay products
    $71.1M+7.1%
  • Vet software & imaging
    $66.9M+15.3%
  • Water
    $39.3M+5.9%
  • Dx capital instruments
    $38.9M-10.5%
  • LPD
    $33.4M-1.7%
  • Dx services & accessories
    $27.1M-2.1%
  • Other
    $7.33M-32.7%

Forward guidance

The Company expects full year 2021 revenue growth of 13% - 15.5% on a reported basis and 11.5% - 13.5% revenue growth on an organic basis. The Company also expects EPS of $7.39 - $7.71, reflecting a targeted 50 - 100 basis points of comparable constant currency operating margin improvement, building on strong 2020 performance.

Tailwinds

  • Revenue growth rate impact 1.5%-2.0%
  • CAG Diagnostics recurring revenue growth rate impact ~ 1.5%
  • Operating margin growth impact ~ 10 bps
  • EPS impact ~ $0.14
  • EPS growth impact ~ 2.0%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

+0.7%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+2.8%

Avg return

30 days after

43%

30 / 69 earnings

Positive

+27.5%

Q2 2025

Best reaction

-18.9%

Q1 2015

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+3.4%-0.6%-0.1%
Q4 2025-4.8%-3.9%-3.2%
Q3 2025+14.9%+12.5%+15.3%
Q2 2025+27.5%+22.9%+18.4%
Q1 2025+9.0%+9.5%+18.7%
Q4 2024+11.1%+8.9%+3.6%
Q3 2024-7.5%-7.8%-6.5%
Q2 2024+2.6%+6.1%+3.1%
Q1 2024-3.4%-3.2%+0.9%
Q4 2023+7.6%+8.5%+5.8%
Q3 2023+5.0%+5.9%+20.8%
Q2 2023-6.4%-9.1%-7.8%
Q1 2023-2.2%-0.2%-4.0%
Q4 2022+5.2%+0.7%-0.0%
Q3 2022+3.6%+3.4%+22.1%
Q2 2022+2.2%+2.4%-12.1%
Q1 2022-11.7%-20.9%-14.5%
Q4 2021+5.0%+0.8%+4.3%
Q3 2021-6.1%-4.4%-10.1%
Q2 2021-3.6%-0.8%-5.1%
Q1 2021-3.6%-1.0%+0.1%
Q4 2020-1.4%+2.1%-1.3%
Q3 2020+0.5%+5.0%+7.4%
Q2 2020+4.8%+5.8%+2.6%
Q1 2020-0.7%+3.4%+13.3%
Q4 2019-2.8%-3.3%-10.3%
Q3 2019+1.1%-3.5%-8.1%
Q2 2019-4.7%-4.1%+2.7%
Q1 2019+4.5%+8.6%+7.7%
Q4 2018-4.5%-1.9%+1.5%
Q3 2018-3.4%-4.6%-3.9%
Q2 2018-1.7%-0.8%+3.7%
Q1 2018+6.0%+5.5%+10.0%
Q4 2017-0.4%-3.7%-0.7%
Q3 2017-3.1%-5.4%-4.9%
Q2 2017-9.2%-8.3%-6.6%
Q1 2017+0.6%-1.5%+2.9%
Q4 2016+15.7%+16.6%+19.8%
Q3 2016-1.6%-0.9%+6.6%
Q2 2016+15.5%+16.6%+21.0%
Q1 2016+5.6%
Q4 2015+10.4%
Q3 2015-8.8%
Q2 2015+9.4%
Q1 2015-18.9%
Q4 2014-3.1%
Q3 2014+9.8%
Q2 2014-2.7%
Q1 2014+2.9%
Q4 2013+6.5%
Q3 2013-1.0%
Q2 2013-0.6%
Q1 2013-6.4%
Q4 2012-3.5%
Q3 2012-1.1%
Q2 2012-5.3%
Q1 2012-3.4%
Q4 2011-0.5%
Q3 2011+3.2%
Q2 2011+6.3%
Q1 2010+0.0%
Q1 2011+3.0%
Q4 2008-3.9%
Q4 2010-3.9%
Q3 2009-1.4%
Q3 2010-1.4%
Q4 2009-2.7%
Q2 2009-2.7%
Q2 2010-2.7%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro